Naoki Furuya

31PUBLICATIONS
146CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesPredictive and prognostic markersElectrical energy transmission, networks and systems
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (31)

|Oct 15, 2026
Clinicopathological Features of DLL3 Expression and T-Cell Infiltration in LCNEC: Insights From Pathology and Clinical Response to Tarlatamab.

|Aug 27, 2026
Surgical Complexity and Perioperative Feasibility Following Neoadjuvant Chemotherapy, Chemoradiotherapy, or Chemoimmunotherapy in Stage II-III Non-Small Cell Lung Cancer: A Retrospective Single-Institution Study.

|Jun 29, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

|Feb 03, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0.

Joshua E Reuss, Lyudmila Bazhenova, Nofisat Ismaila

|Feb 03, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0.

Sonam Puri, Natasha B Leighl, Nofisat Ismaila

|Aug 22, 2025
EGFR Exon 20 insertions in NSCLC: from biology to amivantamab, optimal treatment strategy and emerging therapeutics.

Naoki Furuya

Pageof 6

Frequent Collaborators

6 joint publications

Natasha B Leighl

6 joint publications

Nofisat Ismaila

6 joint publications

Hisashi Saji

6 joint publications

Ibrahim Hanna Azar